Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 69Neoplasms 20Neoplasm Metastasis 12Brain Neoplasms 4Stomach Neoplasms 2Recurrence 2Osteitis Deformans 2Inflammatory Breast Neoplasms 2Head and Neck Neoplasms 2HER2 Positive Metastatic Breast Cancer 2Esophageal Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER-2 Gene Amplification 1Glioma 1Glioblastoma 1Diarrhea 1Carcinoma 1Breast Diseases 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

Octreotide 3Irinotecan 2maltodextrin 1lanreotide 1PHY 906 1Leucovorin 1Lapatinib 1Fluorouracil 1Drugs, Investigational 1Capecitabine 1Calcium Aluminosilicate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Diarrhea × Lapatinib × Clear all
NCT02294786 2019-07-15

Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer

Novartis

Phase 2 Terminated
62 enrolled 25 charts
Breast

Breast Neoplasms, Diarrhea, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡